Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder

References

• Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.
   PubMed Web of Science ®Google Scholar
• Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82–88. doi:10.1016/j.biopsych.2019.06.020
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550
   PubMed Web of Science ®Google Scholar
• Vorspan F, Hjelmström P, Simon N, et al. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019;16(9):907–914. doi:10.1080/17425247.2019.1649252
   PubMed Web of Science ®Google Scholar
• Chappuy M, Trojak B, Nubukpo P, et al. Prolonged-release buprenorphine formulations: perspectives for clinical practice. Therapies. 2020;75(5):397–406. doi:10.1016/j.therap.2020.05.007
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly sub-cutaneous buprenorphine depot (CAM2038) in the treatmentof adult outpatients with opioid use disorder. Addiction. 2019;114(8):1416–1426. doi:10.1111/add.14636
   Web of Science ®Google Scholar
• Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, rando-mised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2019;393(10173):778–790. doi:10.1016/S0140-6736(18)32259-1
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid depen-dence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108(12):2141–2149. doi:10.1111/add.12315
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment ofopioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576–1583. doi:10.1001/jama.2010.1427
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Lofwall M, Kim S, et al. Effect of buprenorphine implants on illicit opioid useamong abstinent adults with opioid dependence treated withsublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316(3):282–290. doi:10.1001/jama.2016.9382
   PubMed Web of Science ®Google Scholar
• Tompkins CNE, Neale J, Strang J. Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treat. 2019;104:64–71. doi:10.1016/j.jsat.2019.06.007
   Web of Science ®Google Scholar
• Neale J, Tompkins CNE, McDonald R, Strang J. Implants and depot injections for treating opioid dependence: qualitative study of people who use or have used heroin. Drug Alcohol Depend. 2018;189:1–7. doi:10.1016/j.drugalcdep.2018.03.057
   PubMed Web of Science ®Google Scholar
• Larance B, Degenhardt L, Grebely J, et al. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction. 2020;115(7):1295–1305. doi:10.1111/add.14941
   PubMed Web of Science ®Google Scholar
• Boutwell AE, Nijhawan A, Zaller N, Rich JD. Arrested on heroin: a national opportunity. J Opioid Manag. 2007;3(6):328–332. doi:10.5055/jom.2007.0021
   PubMedGoogle Scholar
• Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32–43. doi:10.1016/j.jsat.2018.12.003
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560–1579. doi:10.1016/S0140-6736(19)32229-9
   PubMed Web of Science ®Google Scholar
• Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002. doi:10.1371/journal.pmed.1003002
   PubMed Web of Science ®Google Scholar
• Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abus. 2020;41(2):150–154. doi:10.1080/08897077.2019.1695706
   PubMed Web of Science ®Google Scholar
• Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122–131. doi:10.1016/j.drugalcdep.2016.11.032
   PubMed Web of Science ®Google Scholar
• Tompkins CN, Wright NM, Waterman MG, Sheard L. Exploring prison buprenorphine misuse in the United Kingdom: a qualitative study of former prisoners. Int J Prison Health. 2009;5(2):71–87. doi:10.1080/17449200902880482
   Google Scholar
• Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019;103:1–8.
   PubMed Web of Science ®Google Scholar
• Molfenter T, Vechinski J, Taxman FS, Breno AJ, Shaw CC, Perez HA. Fostering MOUD use in justice populations: assessing the comparative effectiveness of two favored implementation strategies to increase MOUD use. J Subst Abuse Treat. 2021;17:108370. doi:10.1016/j.jsat.2021.108370
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Key messages | opioid dependence: buprenorphine prolonged-release injection (Buvidal) | advice | NICE [Internet]. Evid Summ [ES19]. NICE; 2019. Available from: https://www.nice.org.uk/advice/es19/chapter/Key-messages. Accessed March 1, 2021.
   Google Scholar
• Rolland B, Trojak B, Nourredine M, et al. Determinants of interest in extended-released buprenorphine: a survey among 366 French patients treated with buprenorphine or methadone. Drug Alcohol Depend. 2021;220:108492. doi:10.1016/j.drugalcdep.2020.108492
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499. doi:10.1016/j.ijsu.2014.07.013
   PubMed Web of Science ®Google Scholar
• French monitoring centre for drugs and drug addiction (OFDT) - Drug uses in prison - practices, consequences and responses (French). OFDT; 2019. Available from: https://www.ofdt.fr/BDD/publications/docs/epfxcpzc.pdf. Accessed May 4, 2021.
   Google Scholar
• Ferguson WJ, Johnston J, Clarke JG, et al. Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails. Health Justice. 2019;7(1):19. doi:10.1186/s40352-019-0100-2
   PubMedGoogle Scholar
• Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–46. doi:10.1097/00001648-199001000-00010
   PubMedGoogle Scholar